GlassScriptPhysician profile
Reza Govashiri
NPI 1255346797
$2,718.58
in general payments reported to CMS, 2019-2025
22 companies · $601 in 2025
The $601 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $620 · 2020: $28.92 · 2021: $207 · 2022: $296 · 2023: $523 · 2024: $443 · 2025: $601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,553 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,552.97 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,058.98 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Wavewriter Alpha Prime 16, Watchman Access System |
| Astrazeneca Pharmaceuticals LP | $332.63 | 2019-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $238.75 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $186.15 | 2019-2025 | Otezla, Repatha, Evenity |
| Edwards Lifesciences Corporation | $144.63 | 2021-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Lilly USA, LLC | $100.69 | 2025 | Mounjaro |
| Pfizer INC. | $97.63 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $94.72 | 2022-2023 | |
| Inari Medical, INC. | $66.78 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Merck Sharp & Dohme LLC | $64.97 | 2019-2025 | Capvaxive, Gardasil 9, Keytruda |
| Janssen Pharmaceuticals, INC | $57.41 | 2019-2022 | |
| Exact Sciences Corporation | $46.17 | 2024-2025 | Cologuard Collection Kit |
| Ucb, INC. | $43.61 | 2024 | Nayzilam |
| Abbvie INC. | $31.53 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $26.00 | 2024 | Jynarque |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $24.64 | 2025 | Shingrix, Arexvy |
| Sumitomo Pharma America, INC. | $20.47 | 2025 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $20.20 | 2024 | Zoryve |
| Astellas Pharma US INC | $17.41 | 2019 | |
| Ibsa Pharma INC. | $16.16 | 2022 | |
| Allergan, INC. | $15.45 | 2020 | |
| Calliditas Therapeutics US INC. | $13.60 | 2023 | Tarpeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reza Govashiri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.